BioNTech

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Employees: 6.1K

Market Cap: $20.7B

Website: http://www.biontech.de

Introduction: BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in M...

Clinical Trials

A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

Phase 2

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b5 Bivalent (WT/OMI BA.2)
Biological: BNT162b2 Bivalent (WT/OMI BA.4/BA.5)
Biological: BNT162b7 Bivalent (Original/OMI BA.4/BA.5)
Biological: BNT162b5 Bivalent (Original/OMI BA.4/BA.5)
Biological: BNT162b6 Bivalent (Original/OMI BA.4/BA.5)
Biological: BNT162b7 Monovalent (OMI BA.4/BA.5)
Biological: BNT162b2 Bivalent (WT/OMI BA.1)

First Posted Date: 2022-07-25

Last Posted Date: 2024-04-11

Lead Sponsor: BioNTech SE

Target Recruit Count: 1454

Registration Number: NCT05472038

Locations: 🇺🇸
Bayview Research Group, LLC, Valley Village, California, United States
🇺🇸
Clinical Research Professionals, Chesterfield, Missouri, United States
🇺🇸
PharmQuest Life Sciences, LLC, Greensboro, North Carolina, United States

and more 28 locations

A Clinical Trial in Healthy Volunteers to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Phase 1

Recruiting

Conditions: Genital Herpes Simplex Type 2

Interventions: Biological: BNT163
Other: Placebo

First Posted Date: 2022-06-27

Last Posted Date: 2024-10-16

Lead Sponsor: BioNTech SE

Target Recruit Count: 288

Registration Number: NCT05432583

Locations: 🇺🇸
Alliance for Multispecialty Research, LLC, Tempe, Arizona, United States
🇺🇸
Great Lakes Clinical Trials - Flourish Research, Chicago, Illinois, United States
🇺🇸
Accellacare Raleigh Medical Group, Raleigh, North Carolina, United States

and more 3 locations

Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age

Phase 3

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2
Other: Placebo
Biological: Seasonal Inactivated Influenza Vaccine

First Posted Date: 2022-04-04

Last Posted Date: 2024-06-12

Lead Sponsor: BioNTech SE

Target Recruit Count: 1134

Registration Number: NCT05310084

Locations: 🇦🇺
Barwon Health, Geelong, Victoria, Australia
🇳🇿
New Zealand Clinical Research (Auckland), Grafton, Auckland, New Zealand
🇳🇿
P3 Research - Hawke's Bay, Havelock North, Hawke's BAY, New Zealand

and more 23 locations

Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Biological: BNT142

First Posted Date: 2022-03-02

Last Posted Date: 2024-12-19

Lead Sponsor: BioNTech SE

Target Recruit Count: 330

Registration Number: NCT05262530

Locations: 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸
START Madrid-FJD Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre - Centro de Actividades Ambulatorias, Madrid, Spain

and more 21 locations

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: BNT116
Biological: Cemiplimab
Drug: Docetaxel
Biological: CTLA4 antibody
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2021-12-02

Last Posted Date: 2024-11-21

Lead Sponsor: BioNTech SE

Target Recruit Count: 160

Registration Number: NCT05142189

Locations: 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
NEXT Virginia, Fairfax, Virginia, United States

and more 35 locations

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Phase 2

Completed

Conditions: SARS-CoV-2 Infection
COVID-19
SARS-CoV-2 Acute Respiratory Disease
SARS (Disease)

Interventions: Biological: Monovalent BNT162b2 (B.1.617.2)
Biological: BNT162b2
Other: Observational
Biological: Monovalent BNT162b2 (B.1.1.529.1)
Biological: Multivalent BNT162b2 (B.1.1.7 + B.1.617.2)
Biological: Monovalent BNT162b2 (B.1.1.7)

First Posted Date: 2021-08-13

Last Posted Date: 2024-11-22

Lead Sponsor: BioNTech SE

Target Recruit Count: 1380

Registration Number: NCT05004181

Locations: 🇺🇸
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
🇺🇸
North Texas Infectious Diseases Consultants, Dallas, Texas, United States
🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States

and more 32 locations

To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.

Phase 3

Completed

Conditions: SARS-CoV-2 Infection
COVID-19

Interventions: Biological: BNT162b2
Other: Placebo
Biological: BNT162b2 OMI
Biological: Combination BNT162b2 and BNT162b2 OMI
Biological: Combination (Bivalent) BNT162b2 and BNT162b2 OMI

First Posted Date: 2021-07-09

Last Posted Date: 2023-06-13

Lead Sponsor: BioNTech SE

Target Recruit Count: 16385

Registration Number: NCT04955626

Locations: 🇺🇸
Wenatchee Valley Hospital, Wenatchee, Washington, United States
🇿🇦
Tiervlei Trial Centre, Cape Town, Western CAPE, South Africa
🇺🇸
Kaiser Permenente Medical Center Infectious Disease, Los Angeles, California, United States

and more 137 locations

A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects

Phase 2

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2s01
Biological: BNT162b2

First Posted Date: 2021-07-02

Last Posted Date: 2022-09-21

Lead Sponsor: BioNTech SE

Target Recruit Count: 137

Registration Number: NCT04949490

Locations: 🇩🇪
University Hospital Heidelberg, Clinical Pharmacology, Heidelberg, Germany
🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
🇩🇪
University Hospital Frankfurt, Infectiology, Frankfurt, Germany

and more 1 locations

Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years

Phase 2

Completed

Conditions: SARS-CoV-2 Infection, COVID19

Interventions: Biological: BNT162b2

First Posted Date: 2021-05-21

Last Posted Date: 2024-10-09

Lead Sponsor: BioNTech SE

Target Recruit Count: 124

Registration Number: NCT04895982

Locations: 🇺🇸
Ochsner Medical Center Kenner, Kenner, Louisiana, United States
🇩🇪
Studiengesellschaft BSF UG., Halle (Saale), Germany
🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

and more 21 locations

A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults

Phase 3

Completed

Conditions: COVID-19
SARS-CoV-2 Infection

Interventions: Biological: BNT162b2

First Posted Date: 2021-03-25

Last Posted Date: 2022-12-23

Lead Sponsor: BioNTech SE

Target Recruit Count: 629

Registration Number: NCT04816669

Locations: 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States
🇺🇸
Clinical Research Atlanta, Stockbridge, Georgia, United States

and more 18 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy